The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modifications occurred within the 5 0 hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.
Introduction
The development of multidrug resistance (MDR) following chemotherapy treatment imposes severe limitations on the efficacy of anticancer agents. Overexpression of the MDR1 gene product, P-glycoprotein (Pgp), is a well-established mediator of MDR, and has been correlated with increased disease resistance, reduced probability in obtaining complete remission, and a shorter remission duration and survival period in cancer patients (Kuwazuru et al., 1990; Marie et al., 1991; Pirker et al., 1991; Campos et al., 1992; Zhou et al., 1992; te Boekhorst et al., 1993; Wood et al., 1994; Zochbauer et al., 1994; Leith et al., 1997; van den Heuvel-Eibrink et al., 1997) . Pgp may be intrinsically expressed, or acquired following chemotherapeutic drug treatment. The molecular mechanisms responsible for the acquisition of Pgp expression following chemotherapy have not been defined, although several models have been put forward. In the first model 'selection and expansion', proposed almost two decades ago, tumors overexpressing Pgp develop following the drug-induced selection of a small population of Pgp high cells that subsequently becomes expanded and eventually overgrows the sensitive Pgp Àve /Pgp low cell population (Goldie and Coldman, 1984) . Alternatively, according to the 'activation model', chemotherapeutic drugs can directly activate the multidrug resistance 1 (MDR1) gene, leading to Pgp overexpression and drug resistance (Abolhoda et al., 1999; Hu et al., 1999a) . More recently, drug-induced increases in MDR1 expression in leukemic cell lines have also been attributed to increases in mRNA stability (Yague et al., 2003) .
Evidence from cell lines and in vivo studies of patients undergoing chemotherapy demonstrate that MDR1 can be rapidly upregulated following exposure to chemotherapeutic drugs (Chaudhary and Roninson, 1993; Hu et al., 1995 Hu et al., , 1999a Abolhoda et al., 1999) , supporting the activation model. For example, ex vivo treatment of AML blasts isolated from newly diagnosed patients prior to induction chemotherapy resulted in the rapid upregulation of MDR1 expression, concomitant with increases in Pgp expression within 16 h of treatment, and in one AML patient increased Pgp expression in vivo was observed after only 4 h of chemotherapy (Hu et al., 1999a) . Furthermore, cells isolated from five patients undergoing lung perfusion with doxorubicin were shown to increase in MDR1 expression within as little as 50 min after treatment commencement (Abolhoda et al., 1999) . While these studies support the 'activation model' for the development of Pgp þ ve tumors, very little is known of the molecular mechanism(s) of drug-induced MDR1 activation.
Eukaryotic gene transcription is a highly regulated process that is controlled at multiple levels. DNA methylation, histone modifications, nucleosomal remodeling and transcription factor recruitment are coordinated to regulate chromatin structure and allow promoter accessibility to the basal transcriptional machinery. Recent studies have indicated that transcriptional regulation of MDR1 is controlled at the chromatin level. In both tumor cell lines and patient samples, the density of MDR1 promoter methylation inversely correlated with basal gene expression, indicating that this epigenetic process plays an important role in regulating MDR1 expression (Kantharidis et al., 1997; Nakayama et al., 1998; Kusaba et al., 1999; El-Osta et al., 2002) . Recently, methylation of the MDR1 promoter was shown to be decreased in patients having undergone chemotherapy treatment, correlating with increased MDR1 mRNA expression. Analysis of patient samples at diagnosis, and at relapse, showed that tumor cells predominantly contained a hypomethylated MDR1 promoter after chemotherapy, which correlated with enhanced expression of Pgp (Tada et al., 2000) . This raised the possibility that chemotherapeutic drugs may actively induce DNA demethylation at the MDR1 promoter to mediate gene expression. However, the presence of Pgp-expressing tumor cells containing a hypomethylated MDR1 promoter upon relapse may merely represent the selection and expansion of those cells during drug treatment. It is not known whether chemotherapeutic drugs have chromatin-modifying capacities that can be directed towards genes associated with a gain in cell survival, such as MDR1.
In the following study, we show that MDR1 upregulation occurs due to drug-induced transcriptional activation. Using a combination of bisulfite genomic sequencing and chromatin immunoprecipitation (ChIP), we demonstrate that drug-induced MDR1 upregulation did not involve dramatic changes to the DNA methylation profile within the 5 0 region of the MDR1 locus. Upregulation was dependent on the methylation status of the promoter at the time of onset of drug treatment, with an inverse correlation between hypermethylation of the 5 0 region of MDR1 and upregulation in response to certain chemotherapeutic drugs. We show that distinct changes in the spatial and temporal patterns of histone modifications were only associated with chemotherapeutic drug-induced MDR1 upregulation. The findings of this study demonstrate that MDR1 gene activation involves specific epigenetic changes, and that a posttranscriptional mechanism involving mRNA stability may contribute to increased gene expression. These data are consistent with a dual model to describe the development of Pgp þ ve MDR tumors, involving both 'selection' of cells that contain a hypomethylated MDR1 promoter and transcriptional activation of the MDR1 gene following specific modifications of the chromatin at the locus.
Results

MDR1 is upregulated by chemotherapeutic drugs
In order to study the effect of chemotherapeutic drugs on MDR1 induction, we examined two human tumor cell lines that consistently responded to short-term drug treatment by upregulating MDR1 expression. CEMBcl2, an acute T-cell leukemia cell line with stable overexpression of the antiapoptotic protein, Bcl2, had very low basal MDR1 expression when analysed by quantitative real-time PCR (RTQ-PCR) (data not shown). As overexpression of Bcl-2 inhibits apoptosis induced by most chemotherapeutic drugs (Johnstone et al., 2002) , this cell line was used to determine the gene-regulatory effects of cytotoxic drugs in the absence of cell death. The colon carcinoma cell line, SW620, had a higher basal level of MDR1 expression (up to 60-fold difference) when compared to CEM-Bcl2 cells (data not shown), and was used to determine if chemotherapeutic drugs could further enhance MDR1 expression when the gene was already transcriptionally active.
MDR1 mRNA levels were upregulated 4-6-fold following exposure of CEM-Bcl2 cells to the chemotherapeutic drugs daunorubicin (DNR) and etoposide (ETOP) for 8 h (Figure 1a) . Treatment with the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), also upregulated MDR1 expression in CEM-Bcl2 cells (Figure 1a ), providing evidence that the MDR1 gene is responsive to histone hyperacetylation in these cells. Further marked increases in MDR1 expression were evident when CEM-Bcl2 cells were treated for 24 h, with DNR and ETOP inducing MDR1 expression over 200-fold (Figure 1b) , while prolonged treatment with TSA did not further enhance MDR1 expression. Drug treatments had little effect on the viability of CEM-Bcl2 cells at the doses used in this system. Interestingly, the chemotherapeutic drug vincristine (VINC) did not upregulate MDR1 mRNA in a time-or concentrationdependent manner (Figure 1a , b; data not shown). The ability of TSA and DNR to upregulate MDR1 mRNA levels was not restricted to CEM-Bcl2 cells, as similar results were seen in SW620 cells. Treatment of SW620 cells for 24 h upregulated MDR1 mRNA levels 10-13-fold ( Figure 1c ).
It had recently been shown that increases in MDR1 expression following chemotherapeutic drug treatment may result from enhanced mRNA stability rather than increased transcription (Yague et al., 2003) . To determine whether drug-induced increases in MDR1 mRNA shown in Figure 1a -c were due to transcriptional activation, we used two different approaches. CEMBcl2 and SW620 cells were drug treated in the presence of the transcriptional inhibitor drug, actinomycin D. Actinomycin D inhibited drug-induced MDR1 upregulation in CEM-Bcl2 cells (Figure 2a ) and SW620 cells (data not shown), indicating that MDR1 was regulated at the transcriptional level in our systems.
To confirm that upregulation was due to increased transcriptional activity, we assayed for MDR1 premRNA (unspliced, newly transcribed RNA) over a 24 h treatment of CEM-Bcl2 and SW620 cells with DNR, using RTQ-PCR (Figure 2b ). Negative controls lacking reverse transcriptase and PCR analyses of MDR1 promoter sequences ( Figure 2b ) were included as controls for contaminating genomic DNA. Genomic DNA contamination of total RNA preparations was negligible, as assayed by RTQ-PCR (see Materials and methods). In CEM-Bcl2 cells, MDR1 pre-mRNA was detectable after 8 h of DNR treatment, and steadily increased over 24 h (Figure 2c ). MDR1 mature mRNA (spliced, steady-state RNA) was also increased after 8 h of DNR treatment, and continued to rapidly increase after this time, greater than the rate observed for the pre-mRNA. Increases in pre-mRNA transcripts were apparent in SW620 cells after 4 h of DNR treatment, and steadily increased up until 20 h (Figure 2d ), after which time the levels plateaued. The time course for mature mRNA transcripts showed a similar increase to that of pre-mRNA levels over 24 h. Taken together, our data show that basal MDR1 mRNA levels were upregulated following treatment with TSA, DNR and ETOP in CEM-Bcl2 and SW620 cells, and indicate that drug-induced upregulation of MDR1 is mediated by transcriptional activation.
As drug-induced increases in MDR1 mRNA steady states appear to be mediated by transcriptional activation, we examined whether corresponding increases in Pgp protein were evident. Pgp expression was increased in SW620 cells following 24 h of TSA and DNR treatment, as measured by Western analysis (Figure 3a) . In contrast, Pgp expression was not detectable after 24 h of drug treatment in CEM-Bcl2 cells (Figure 3b ), despite evidence of increased transcriptional activity following drug treatment with TSA, DNR and ETOP.
Previously, drug-induced increases in MDR1 steadystate mRNA, but lack of corresponding Pgp protein expression, have been attributed to mRNA stability (Yague et al., 2003) . To determine whether upregulated MDR1 expression in CEM-Bcl2 and SW620 cells could also be attributed to mRNA stability, we measured the half-life of MDR1 mRNA in untreated cells, and cells that had been treated with DNR, by inhibiting transcription with actinomycin D over 12 h. The halflife of MDR1 mRNA in untreated SW620 cells was approximately 4 h ( Figure 4a ). DNR treatment, prior to the addition of actinomycin D, did not significantly affect the half-life of the mRNA in these cells (Figure 4a ). In comparison, the half-life of MDR1 mRNA transcripts in CEM-Bcl2 cells pretreated with DNR was not measurable within the 12-h time frame, in distinct contrast to untreated CEM-Bcl2 cells where the MDR1 mRNA had a half-life of 4-6 h ( Figure 4b ). The half-life of helix-loop-helix protein (Id2), a short-lived mRNA (Yague et al., 2003) , was not appreciably different between untreated and DNR-treated SW620 (Figure 4c ) and CEM-Bcl2 cells (Figure 4d ), indicating that the stabilization of MDR1 mRNA in CEM-Bcl2 cells after DNR treatment was specific. Transcriptional activation is therefore not the only mechanism accounting for rapid increases in steady-state MDR1 mRNA levels following drug treatment in CEM-Bcl2 cells. Furthermore, increases in steady-state mRNA are not always associated with increased Pgp expression, as identified previously in other leukemic cell lines (Yague et al., 2003) . To further investigate the mechanism of MDR1 transcriptional activation, the capacity of chemotherapeutic drugs to modify MDR1 chromatin was examined. We and others have demonstrated that methylation of the MDR1 promoter regulates the basal transcriptional activity of MDR1 (Nakayama et al., 1998; El-Osta et al., 2002) . CEM-CCRF cells have a hypermethylated MDR1 locus (El-Osta et al., 2002) , and treatment of these cells with TSA or chemotherapeutic drugs for 8 or 24 h did not induce MDR1 gene expression (data not shown), suggesting a dominant hierarchy of DNA methylation relative to histone acetylation. To analyse the methylation profile of the MDR1 promoter in cells conducive to upregulation of MDR1 expression, we used bisulfite genomic sequencing to examine the methylation profile of the MDR1 promoter in CEM-Bcl2 and SW620 cells before and after treatment . When compared to the hypermethylated sequence in CEM-CCRF cells (see El-Osta et al., 2002) , the MDR1 promoter was less methylated in CEM-Bcl2 cells and SW620 cells (Figure 5b and d) . Thus, the basal expression of MDR1 and its susceptibility to upregulation by TSA, DNR and ETOP are dependent on the methylation status of the promoter.
Several studies have suggested that enhanced MDR1 expression in human malignancies following chemotherapy may be attributable to chemotherapeutic drug-induced demethylation of the MDR1 promoter (Nakayama et al., 1998; Tada et al., 2000) . Treatment of CEM-Bcl2 cells with DNR did not significantly alter the DNA methylation profile of the MDR1 5 0 region (Figure 5c ), even though MDR1 expression was increased greater than 200-fold by this agent over the same time course (Figure 1b ). We also tested CEM-Bcl2 cells for their response to treatment with the DNA demethylating agent 5-aza-2-deoxycytidine (AzadC) and TSA, or TSA alone, and found that the combined treatment with TSA and AzadC did not enhance the level of MDR1 upregulation over that seen with TSA alone (Figure 5e ). Similar results were seen in SW620 cells (data not shown). In contrast, we have previously shown that treatment of CEM-CCRF cells with AzadC and TSA, but not TSA alone, resulted in robust activation of MDR1 expression (El-Osta et al., 2002). Therefore, the low level of MDR1 promoter CpG methylation seen in CEM-Bcl2 and SW620 cells, or Quantitation of the relative change in MDR1 expression7standard deviation of three separate PCR amplifications of cDNA samples (see Materials and methods). MDR1 expression was normalized against HMBS expression. The graph shows representative data from three independent experiments. (b) Detecting newly transcribed MDR1 mRNA (pre-mRNA) and steady-state MDR1 mRNA (mature mRNA) transcripts. A two-step RTQ-PCR method was employed. Schematic representation of the MDR1 promoter and transcribed region (not to scale). The transcription start site is designated as þ 1. Pre-mRNA transcripts were detected by a forward primer located in exon 7 and a reverse primer located in intron 7. Mature mRNA transcripts were detected by a forward primer located in exon 7 and a reverse primer located in exon 8. To ensure against genomic DNA contamination, extensive DNase treatments of the RNA preparations were carried out, and PCR analyses of negative controls lacking reverse transcriptase, and promoter sequences (A), were performed (see Materials and methods). other methylated sequences outside of the 1.15 kb region analysed, does not appear to play a significant role in upregulation. Taken together, these findings suggest that chemotherapeutic drugs do not alter the methylation profile of the MDR1 promoter. Moreover, druginduced upregulation of MDR1 occurred only in cells containing a partially demethylated promoter, suggesting that epigenetic changes other than DNA demethylation contribute to the mechanism of upregulation.
Chemotherapeutic drug upregulation correlates with MDR1 promoter histone H3 hyperacetylation
To determine whether treatment of CEM-Bcl2 or SW620 cells with chemotherapeutic drugs induced changes in histone modifications, we assessed the histone H3 and H4, acetylation status in cell lysates, and specifically within the MDR1 5 0 region. Using antibodies specific to di-and tetra-acetylated histone H3 and H4 respectively, we determined that chemotherapeutic drug treatment of CEM-Bcl2 and SW620 cells did not globally change the level of histone H3 and H4 acetylation ( Figure 6a ). As expected, treatment of cells with TSA induced marked hyperacetylation of histones H3 and H4 (Figure 6a ). To directly assess if chemotherapeutic drug-induced activation of MDR1 correlated with changes in histone acetylation within specific regions of the MDR1 locus, we performed ChIP assays. Primer sets encompassing approximately 2.3 kb of the MDR1 locus were used to map changes in histone hyperacetylation following drug treatment (Figure 6b Prolonged treatment of CEM-Bcl2 cells with TSA for 24 h did not further increase H3 hyperacetylation across the MDR1 5 0 region (Figure 6f) , and, surprisingly, H4 hyperacetylation was reduced at 24 h (Figure 6g ). Treatment of CEM-Bcl2 cells with DNR and ETOP for 24 h resulted in increased histone H3 acetylation (up to sevenfold) that spread across the promoter into the coding region of MDR1 (Figure 6f ). The spread of histone H3 hyperacetylation across the MDR1 5 0 region was specific for distinct regions of the MDR1 locus. Region A remained hypoacetylated following DNR and ETOP treatment (less than twofold change), while regions B-E, and, to a lesser extent, region F, showed robust increases in histone H3 hyperacetylation (Figure 6f) . Furthermore, the marked increase in hyperacetylation across the MDR1 promoter following DNR and ETOP treatment remained specific to histone H3 as histone H4 hyperacetylation was not significantly enhanced by these agents over 24 h (Figure 6g ). Changes in drug-induced histone H3 hyperacetylation correlated with the MDR1 upregulation potential, as VINC treatment over 24 h did not result in hyperacetylation of histones H3 or H4 (Figure 6f and g) , and, as shown in Figure 1b , did not induce MDR1 expression.
To assess whether the specific pattern of H3 hyperacetylation within the MDR1 5 0 region following chemotherapeutic drug treatment occurred in other cell lines, we mapped the changes in H3 and H4 acetylation in SW620 cells following exposure to DNR (Figure 6h ). DNR treatment of SW620 cells for 24 h resulted in approximately 2-5-fold changes in histone H3 acetylation in regions D and E, with little or no changes in regions A, B, C and F (Figure 6h) . Region D showed a very distinct increase in H3 hyperacetylation (up to fivefold), and correlated with the region in CEM-Bcl2 cells that was enriched for H3 hyperacetylation following 8 h of DNR and ETOP treatment ( Figure 6d ). As seen in CEM-Bcl2 cells (Figure 6e and g ), DNR treatment of SW620 cells did not result in greater than a twofold change in histone H4 hyperacetylation in any region (Figure 6h ).
To demonstrate a mechanistic link between druginduced histone H3 hyperacetylation within the 5 0 region of MDR1 and upregulation, we drug-treated CEM-CCRF cells and assayed for H3 acetylation enrichment at the MDR1 locus. Drug treatment of CEM-CCRF cells did not activate MDR1 transcription (data not shown) and acetylation of histone H3 was not enriched at the locus (Figure 7a ). DNR treatment of CEM-Bcl2 cells, in the presence of actinomycin D, inhibited upregulation of MDR1 expression (Figure 2a) , correlating with a lack of H3 acetylation enrichment at the MDR1 promoter (Figure 7b ). We further demonstrated a mechanistic link between MDR1 upregulation and enrichment of H3 acetylation, using a detailed time course of DNR treatment of CEM-Bcl2 cells over 8 h. Increases in H3 acetylation at the MDR1 promoter ( Figure 7c ) were apparent earlier than changes in MDR1 expression (Figure 7d ), emphasizing that locus enrichment of H3 acetylation is important for the mechanism of MDR1 upregulation.
Drug-induced histone H3 hyperacetylation is MDR1 promoter specific
To determine whether drug-induced histone H3 hyperacetylation was specific to the MDR1 locus, we assessed the effect of 24 h drug treatment on the expression of the deoxycytidine kinase (dCK) gene that is hypomethylated in CEM-CCRF cells (Leegwater et al., 1998) . Treatment of CEM-Bcl2 cells for 24 h with these drugs did not increase dCK mRNA levels (Figure 8a ). The lack of drug-induced activation of dCK correlated with a lack of histone H3 or H4 hyperacetylation at the promoter (Figure 8b) . Similar results were obtained in the SW620 cell line following a 24 h treatment with DNR (data not shown). Expression and histone acetylation status of the MRP1 gene also did not change following treatment of CEM-Bcl-2 or SW620 cells with chemotherapeutic drugs (data not shown). These experiments therefore demonstrate that increased histone H3 hyperacetylation within the MDR1 5 0 region in response to DNR and ETOP treatment is a gene-specific event and correlates with drug-induced upregulation of MDR1 following exposure to certain chemotherapeutic drugs.
Chemotherapeutic drug treatment results in promoter histone H3K4 methylation
Methylation of histone H3 lysine residue 4 (MeH3K4) is commonly associated with histone hyperacetylation and activated gene expression (Strahl et al., 1999; Litt et al., 2001; Noma et al., 2001; Bernstein et al., 2002; Boggs et al., 2002) . We therefore investigated whether altered MeH3K4 within the MDR1 promoter correlated with MDR1 upregulation by chemotherapeutic drugs, and increased H3 acetylation. Similar to H3 acetylation levels, CEM-Bcl2 and SW620 cells, in comparison to the transcriptionally silenced, CEM-CCRF cell line, had increased levels of MeH3K4, in the order of 30-fold higher in regions B-D of the MDR1 locus (Figure 9a ). However, in contrast to the drug-induced increases in H3 acetylation (Figure 6d) , treatment of CEM-Bcl2 cells for 8 h with TSA, DNR and ETOP did not increase the level of MeH3K4 greater than twofold (Figure 9b ) despite upregulating MDR1 expression (Figure 1a) . However, MeH3K4 levels increased following treatment with TSA and DNR for 24 h (Figure 9c ). TSA treatment induced greater than twofold changes in MeH3K4 across most regions of the MDR1 locus analysed (Figure 9c ), while DNR induced specific targeted increases in MeH3K4 within regions A, D and E (Figure 9c) . Surprisingly, ETOP treatment of CEMBcl2 cells for 24 h, although associated with increased H3 acetylation (Figure 6f ), did not increase the level of MeH3K4 above twofold in any region of the MDR1 locus, while VINC induced a slight increase in MeH3K4 levels in region C (Figure 9c ). The enrichment of MeH3K4 observed after treatment for 24 h of CEMBcl2 cells with TSA and DNR was specific to the MDR1 locus, as changes in excess of twofold did not occur at the dCK promoter (Figure 9d ). Taken together, these data demonstrate a delayed enrichment in MeH3K4 at discrete regions of the MDR1 locus following treatment with specific compounds.
Collectively, the results from this study indicate that chemotherapeutic drug treatment results in epigenetic changes at the MDR1 locus. A complex interplay of H3 acetylation and MeH3K4 histone modifications occurs at the MDR1 locus in response to chemotherapeutic drugs that correlate with MDR1 upregulation. The drug-induced epigenetic modifications were dictated by the CpG methylation state of the MDR1 promoter, and no changes in promoter methylation occurred in response to drug treatment. Transcriptional activation of MDR1, combined with a potential post-transcriptional component, underpinned the mechanism of druginduced upregulation.
Discussion
Three models have been put forward to explain the development of multidrug-resistant tumors through overexpression of Pgp following chemotherapy. In the 'selection and expansion' model, MDR1 overexpression results from chemotherapeutic drug selection and expansion of a small population of Pgp high cells that exist within a heterogeneous mix of tumor cells. A second 'activation' model has been proposed, whereby Pgp high cells are derived from Pgp Àve /Pgp low cells following activation of MDR1 expression by chemotherapeutic drugs. MDR1 mRNA stabilization has also been highlighted as a mechanism that mediates drug-induced increases in MDR1 expression (Yague et al., 2003) . Recently, several groups have demonstrated that basal expression of MDR1 is mechanistically controlled at the chromatin level and that promoter methylation is a dominant epigenetic regulator of MDR1 transcription (Kantharidis et al., 1997; Jin and Scotto, 1998; Nakayama et al., 1998; El-Osta et al., 2002) . Herein, we have demonstrated that chemotherapeutic drugs induce specific epigenetic modifications within the MDR1 region concomitant with MDR1 upregulation. Moreover, we showed that chemotherapeutic drugs activated MDR1 only when the promoter was at least partially hypomethylated, and drug-induced upregulation of MDR1 did not involve further changes in promoter methylation. Interestingly, we demonstrate that upregulation of MDR1 mRNA was mediated by transcriptional activation and in some cell lines was associated with increased mRNA stability. Thus, we propose that the development of Pgp þ ve tumor cells following drug treatment involves aspects of the 'selection/expansion' and 'activation' models. The selection process involves those cells within a heterogeneous tumor population that have at least a partially The timing of the expansion of Pgp þ ve cells following drug treatment and MDR1 upregulation appears to be specific to the cell type and mechanism of induction. As we have demonstrated, MDR1 transcriptional activation is associated with immediate increases in Pgp expression, whereas MDR1 upregulation mediated by mRNA stability is not associated with concomitant Pgp expression, but requires prolonged chemotherapeutic drug exposure (Yague et al., 2003) . Cell models in this study were not exposed to chemotherapeutic drugs longer than 24 h, and therefore we cannot confirm whether CEMBcl2 cells would have produced Pgp expression after longer periods of time, as previously demonstrated in other leukemic cell line models (Yague et al., 2003) . Additionally, we cannot rule out that overexpression of Bcl2 could inhibit protein translation. Bcl2 has been demonstrated to increase VEGF activity by mRNA stability as well as transcriptional activation (Iervolino et al., 2002) . Conversely, cells lacking Bcl2 expression were demonstrated to have decreased mRNA instability (Kinkel and Horton, 2003) , raising the possibility that Bcl2 overexpression could effect MDR1 stability. Therefore, we can only tentatively suggest that a posttranscriptional component involving mRNA stability is involved in drug-induced MDR1 upregulation in these models.
The MDR1 locus in untreated CEM-Bcl2 and SW620 cells was enriched with H3 acetylation and MeH3K4, consistent with other models of transcriptionally active genes or a transcriptionally permissive state of chromatin (Litt et al., 2001; Noma et al., 2001; Santos-Rosa et al., 2002; Schneider et al., 2004) . Upregulation of MDR1 by chemotherapeutic drugs was associated with specific changes in the spatial and temporal patterns of H3, but not H4 acetylation. Changes in H3 acetylation were rapid (within 8 h), and enriched at discrete regions of the MDR1 gene and directly correlated with MDR1 induction following drug treatment. A detailed time course over 8 h in CEM-Bcl2 cells exposed to DNR demonstrated that changes in H3 acetylation were apparent before increases in MDR1 mRNA, suggesting that epigenetic changes at the MDR1 locus result in gene upregulation. The level of H3 hyperacetylation continued to increase with prolonged chemotherapeutic drug exposure, resulting in spreading of H3 hyperacetylation over the MDR1 promoter. Surprisingly, we found minimal increases in MeH3K4 levels within the MDR1 5 0 region, and were delayed when compared to the kinetic changes in H3 acetylation and MDR1 upregulation, and occurred only with TSA and DNR treatment. The ability of DNR and ETOP to induce epigenetic modifications was not a genome-wide event as other genes, including the related MRP1 gene, and the dCK gene, which contains a hypomethylated promoter, were not affected by these agents. Interestingly, upregulation of MDR1 and acetylation of histone H3 within the MDR1 5 0 region were only seen using DNR and ETOP and not with VINC, although VINC treatment did slightly elevate the level of MeH3K4 in region C (Figure 9c) , and caused decreases in both acetylation and methylation in other regions. DNR and ETOP are structurally diverse compounds that induce DNA damage by affecting topoisomerase II, while VINC is a microtubule-destabilizing compound (Ferguson et al., 1988) . Whether the ability to induce topoisomerase II interference is an important mechanism for drugs inducing specific epigenetic changes at the MDR1 locus and subsequent upregulation is not known. Given that DNR and ETOP did not globally increase H3 acetylation levels in CEM-Bcl2 and SW620 cells, it is unlikely that the drugs have a large-scale nonspecific effect on chromatin unrelated to the MDR1 gene. The molecular events that are in effect following DNA damage to mediate specific hyperacetylation of MDR1 are currently under investigation. A related microtubule destabilizing compound, vinblastine, has previously been demonstrated to upregulate MDR1 expression in other cell lines (Chaudhary and Roninson, 1993; Yague et al., 2003) . Therefore, it is possible that the inability of VINC to upregulate MDR1 expression in CEM-Bcl2 cells may be a cell-line-specific effect. The decreases in acetylation and methylation at the MDR1 locus in response to VINC treatment highlight the potential of this drug to modify chromatin, and potentially activate MDR1 expression in other cell line models.
The MDR1 CpG methylation state is correlated with transcriptional competence Methylation of the MDR1 promoter transcriptionally silences basal MDR1 expression in cell line models and clinical samples (Kantharidis et al., 1997; Nakayama et al., 1998; Kusaba et al., 1999; Tada et al., 2000; Toyota et al., 2001; El-Osta et al., 2002; Garcia-Manero et al., 2002; Harikrishnan et al., 2005) . Moreover, we have shown herein that chemotherapeutic drugs activate MDR1 transcription only when the promoter is significantly hypomethylated. It has been suggested that the upregulation of MDR1 expression in cancer cells following chemotherapy treatment may be attributable to a loss of MDR1 promoter methylation. Indeed, it has been shown that Pgp þ ve tumor cells obtained from patients post-therapy contain a hypomethylated MDR1 promoter (Nakayama et al., 1998; Tada et al., 2000) . Our data showing that DNR did not mediate the demethylation of the MDR1 promoter do not support the hypothesis that chemotherapeutic drugs may actively cause DNA demethylation. Thus, tumor cells containing a hypomethylated, transcriptionally active MDR1 5 0 region isolated from patients who have previously received chemotherapy may merely reflect the development of malignancies that have undergone the selection, expansion and transcriptional activation processes detailed above.
Drug-induced chromatin modifications correlate with MDR1 upregulation
In this study, we have mapped both temporal and spatial changes in histone H3 and H4 acetylation levels on the MDR1 5 0 region in response to chemotherapeutic drug treatment. We have demonstrated for the first time that chemotherapeutic drugs can have a specific effect on the MDR1 locus to increase H3 acetylation, but not H4 acetylation, correlating with MDR1 upregulation. The associated changes in histone H3 acetylation correlated only with drugs that upregulated MDR1. These results are consistent with other studies demonstrating that targeted increases in histone hyperacetylation dictate gene activation (Chen et al., 1999; Parekh and Maniatis, 1999; Christenson et al., 2001) . Interestingly, anthracyclines can induce cell cycle regulatory genes such as p21, although the mechanism of gene activation is poorly defined (Radosevic et al., 2001) .
The observation that drug-induced upregulation of MDR1 correlated with H3 hyperacetylation but not H4 hyperacetylation is not specific to MDR1. Differential histone acetylation patterns have been demonstrated in other gene activation models (Chen et al., 1999; Parekh and Maniatis, 1999; Sambucetti et al., 1999; Christenson et al., 2001) , indicating that post-translational modification of histone tails can differ depending on the genetic loci and the stimulating agent. It remains to be determined whether other stimuli that can activate MDR1, such as heat shock and UV irradiation, induce a pattern of promoter histone covalent modifications similar to chemotherapeutic drugs.
Previously, most artificial reporter gene assays and mutational deletion studies have only examined the role of trans-factor binding and cis-regulatory elements upstream of the transcription initiation start site in relation to MDR1 transcriptional control. Interestingly, we find that early changes in H3 acetylation that correlate with MDR1 upregulation were associated with a region within intron 1 of the MDR1 gene, suggesting that binding sites for trans-acting factors within this region may be important in endogenous MDR1 upregulation by chemotherapeutic drugs.
H3K4 methylation and MDR1 transcriptional control
In contrast to the rapid increase in H3 acetylation following drug treatment, changes in the level of MeH3K4 on the MDR1 locus in response to TSA and DNR were delayed and reduced, and, in the case of DNR, restricted to specific regions of the promoter. It has been previously suggested that histone hyperacetylation precedes and facilitates MeH3K4 (Li et al., 2002) . However, treatment with TSA and DNR for 8 h induced MDR1 transcription and histone hyperacetylation within the MDR1 5 0 region, but significant hypermethylation (greater than twofold) of H3K4 was not observed until 16 h later (Figure 9b, c) . The differential effect of chemotherapeutic drugs and TSA on MeH3K4 associated with the MDR1 locus may be as a result of the difference in the ability of these agents to hyperacetylate histone H4 or invoke other histone post-translational modifications not studied in this report. The results suggest that increased MeH3K4 is not required for MDR1 gene induction with DNR and ETOP. However, the increased level of MeH3K4 in both CEM-Bcl2 and SW620 cells compared to transcriptionally silenced MDR1 chromatin in CEM-CCRF cells indicates a role for MeH3K4 in maintaining an active, or potentially active state, as suggested from models in yeast and chicken (Santos-Rosa et al., 2002; Schneider et al., 2004) . Other histone modifications apart from H3 acetylation and MeH3K4 are potentially involved in the regulation of MDR1 transcription, and it is expected that a complex interplay of modifications, or 'histone code' (Strahl and Allis, 2000; Jenuwein and Allis, 2001) , is involved in marking the MDR1 gene for further associations with activators necessary to drive transcription. Indeed, recent work on developmentally regulated genes in the chicken demonstrated that increases in trimethylated H3K4 were associated with activation of genes, whereas MeH3K4 was more constant, and reflected a role in maintaining a potentially active chromatin state (Schneider et al., 2004) . Future work directed at identifying the enzymatic complexes whose activity is modified and/or are recruited to the MDR1 locus following chemotherapeutic drug treatment will be important in dissecting the MDR1 transcriptional regulatory mechanism. Work by Jin and Scotto (1998) demonstrated that a stably transfected MDR1 promoter construct could be activated by overexpression of the acetyltransferase factor, PCAF. Despite showing an associated link between acetyltransferase activity and MDR1 activation, a direct association of PCAF with the MDR1 promoter upon activation was not demonstrated. Whether chemotherapeutic drugs induce the recruitment of PCAF or other histone acetyltransferases to the MDR1 5 0 region remains under investigation. The data from this study clearly indicate that the histone acetyltransferase and deacetylase ratios are an important component of the mechanism of MDR1 upregulation. A number of HDAC inhibitors are now in clinical trials, with proven anticancer efficiency, but their ability to activate MDR1, and induce overexpression of Pgp, indicates potential pitfalls in their ability to successfully treat cancer. The development and continued testing of this class of anticancer agents would benefit from their testing or application against multidrug-resistant tumours, and their long-term effects on the multidrug-resistant phenotype.
The results of this study suggest that certain chemotherapeutic drugs have the capacity to induce epigenetic modifications at the MDR1 locus. The sensitivity of MDR1 to upregulation following drug treatment was dependent on the methylation status of the promoter, and drug-induced upregulation of the hypomethylated MDR1 gene was associated with increases in H3 acetylation, and to a lesser extent MeH3K4, that were regulated in a temporal and spatial manner. Further deciphering the molecular events that underpin drug-induced MDR1 transcriptional regulation and mRNA stabilization will ultimately contribute to the general knowledge of the mechanisms of gene regulation, and provide valuable information regarding the development of cancer MDR.
Materials and methods
Cell culture and drug treatments CEM-CCRF (El-Osta et al., 2002) , CEM-Bcl2 (a kind gift from David Huang, Walter and Eliza Hall Institute, Melbourne, Australia), CEM-A7R and SW620 cells were grown in RPMI 1640 media supplemented with hepes, gentamicin and 10% fetal calf serum at 371C in a 5% CO 2 atmosphere. CEM-Bcl2 cells were treated with TSA (Upstate Biotechnology, 50 ng/ml), DNR (DBL, 200 ng/ml), VINC sulfate (DBL, 500 ng/ml) or ETOP (DBL, 500 ng/ml). SW620 cells were treated with TSA (100 ng/ml) or DNR (1 mg/ml). CEM-Bcl2 cells were treated with TSA or AzadC, or a combination thereof as detailed previously for CEM-CCRF cells (El-Osta et al., 2002) . Briefly, cells were either untreated, or treated with TSA (50 ng/ml), AzadC (1 mM) or a combination of TSA and AzadC for 36 h. Cells were resuspended in new RPMI-supplemented media, and new applications of the same drugs and concentrations were applied to the cells for 16 h. Following 16 h, this process was repeated, and the cells were drug treated for further 16 h. For the inhibition of new RNA synthesis studies, CEM-Bcl2 and SW620 cells were treated with 5 mg/ml ActinomycinD (Sigma) 1 h prior to the addition of TSA, or chemotherapeutic drugs. For the determination of RNA half-lives, CEM-Bcl2 and SW620 cells were treated for 24 h with DNR, followed by the addition of actinomycin D at 5 mg/ml. Cells were harvested 1 h later, and periodic time intervals thereafter.
Bisulfite genomic sequencing
Genomic DNA was extracted and bisulfite genomic sequencing carried out as detailed previously (Frommer et al., 1992) . Briefly, genomic DNA was digested with restriction enzymes, denatured and treated with a combination of sodium metabisulfite (Sigma) and hydroxyquinone (Sigma) in the dark. The converted DNA was desalted using a Wizard Purification kit (Promega), eluted in water and desulfonated in the presence of 0.3 M NaOH at 371C for 45 min. The DNA was neutralized with ammonium acetate, ethanol precipitated and redissolved in water. A 1.15 kb region of the MDR1 locus was amplified by PCR. PCR conditions and primer sequences were as described previously (El-Osta et al., 2002) . PCR amplification products were cloned into a pCR-2.1t vector (Invitrogen s ) as per the manufacturer's instructions. PCR inserts were cycle sequenced and analysed by automated sequencing (DNA Sequencing Laboratory, Baker Medical Research Institute, Prahran, Australia).
RNA extraction and cDNA synthesis
Total RNA was extracted from cells using TRIzol s reagent (Invitrogen) according to the manufacturer's instructions, and treated with DNase (Ambion) to remove contaminating genomic DNA. cDNA synthesis was carried out using AMV Reverse Transcriptase (Promega) and random hexamers (Promega) according to the manufacturer's instructions. Total RNA preparations for analysing pre-mRNA and mature mRNA transcripts were extensively treated with DNase (Ambion) to prevent significant genomic DNA contamination. Negative controls lacking reverse transcriptase were included for each RNA sample, and PCR analyses of promoter sequences (region A, Figure 2b ) were also conducted for each sample to control for amplification of contaminating genomic DNA. Experimental values were either neglible, or were subtracted to give newly adjusted values following PCR.
Immunoblotting
Histone proteins from CEM-Bcl2 and SW620 cells were acid extracted. Whole-cell lysates were prepared by lysis with M-PER reagent (Pierce). Equal amounts of protein were size fractionated by 8-15% SDS-PAGE, and transferred to PVDF membranes. Membranes were probed with antibodies against diacetyl histone H3 (Cat. No. 06-599-MN), tetra-acetyl histone H4 (Cat. No. 06-866) (Upstate Biotechnology), Pgp C219 (Sapphire Biosciences) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam). Total protein content from acid extractions was analysed by coomassie blue staining of 15% SDS-PAGE gels.
Chromatin Immunoprecipitation
ChIP was performed on CEM-CCRF, CEM-Bcl2 and SW620 cells (3.5 Â 10 6 ), using a ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions, with some modifications (El-Osta et al., 2001) . Briefly, cells were crosslinked with 1% formaldehyde, quenched with glycine (0.125 M) and resuspended in SDS lysis buffer with the addition of complete protease inhibitor cocktail tablets (Roche Molecular Biochemicals). Samples were sonicated to fragment chromatin to less than 400 bp. Immunoprecipitations were carried out overnight at 41C with 5 mg of anti-diacetyl histone H3 (Cat. No. 06-599-MN), anti-tetra-acetyl histone H4 (Cat. No. 06-866), or anti-dimethyl histone H3K4 (Cat. No. 07-030) (Upstate Biotechnology). Immunoprecipitated DNA was resuspended in 200 ml of TE buffer.
RTQ-PCR
The abundance of RNA transcripts for MDR1, dCK and helix-loop-helix protein (Id2), and the abundance of specific sequences in ChIP samples, was quantitated using RTQ-PCR with the SYBR Green s dye detection method (Applied Biosystems). Hydroxymethyl-bilane synthase (HMBS) or GAPDH was used to normalize expression levels in the cDNA samples. Primer sequences used in cDNA analyses have been published previously for MDR1 (van den Heuvel-Eibrink et al., 2002) , dCK (Mansson et al., 2002) , HMBS (Vandesompele et al., 2002) and GAPDH (Wong et al., 1994) . Primer sequences for Id2 are available on request. Primer sequences for ChIP analyses and the detection of pre-mRNA and mature mRNA were designed using Primer Express 2 s software (Applied Biosystems). Primer sequences are available upon request. Threshold cycle numbers (C t ) were measured in the exponential phase for all cDNA and ChIP samples. MDR1 and dCK cDNA expression was calculated as (Gene C t ÀHMBS C t ¼ C Dt ). C Dt values were converted to relative values using the equation ð100=ð2 
